Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TCRT with free AI briefings, catalyst countdowns, and dilution alerts.

TCRT · Alaunos Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $1.60, 47% below $3.03, its close on the day of its Oct 13 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$124,000 Cash on Hand
0.6mo Cash Runway
Follow TCRT by email Get an email when TCRT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TCRT, unsubscribe in one click. Privacy

📣 What TCRT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Palifosfamide Tromethamine Soft Tissue Sarcoma Phase 3 · NCT01168791 Terminated
Doxorubicin Soft Tissue Sarcoma Phase 3 · NCT01168791 Terminated
Palifosfamide (ZIO-201) Advanced Sarcoma Phase 1/2 · NCT00439686 Completed
Darinaparsin (ZIO-101) Multiple Myeloma Phase 1/2 · NCT00303199 Completed
Veledimex (INXN-1001) Metastatic Breast Cancer Phase 1/2 · NCT02423902 Terminated
Oral Veledimex - Arm 2 (DIPG) Pediatric Brain Tumor Phase 1/2 · NCT03330197 Terminated
Oral Veledimex - Arm 1 (Pediatric Brain Tumor) Pediatric Brain Tumor Phase 1/2 · NCT03330197 Terminated
Neoantigen specific TCR-T cell drug product Gynecologic Cancer Phase 1/2 · NCT05194735 Terminated
Ad-RTS-hIL-12 Melanoma Phase 1/2 · NCT01397708 Completed
Indibulin Metastatic Breast Cancer Phase 1 · NCT01113970 Terminated
DNA Damage-Inducible Transcript 3 Protein Lymphoma Phase 1 · NCT01139359 Withdrawn
Melphalan Lymphoma Phase 1 · NCT00968760 Completed
INXN-3001 Melanoma Phase 1 · NCT00815607 Completed

Also used in these trials (approved or third-party drugs, not TCRT's own candidates): Carboplatin, Etoposide, Aldesleukin, Cemiplimab-Rwlc, Capecitabine, Carmustine, Cytarabine, Nivolumab, Erlotinib Hydrochloride, Interleukin-2.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TCRT holds $124,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $665,500/quarter from operations, an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TCRT files for a raise →

👥 Who Owns TCRT

Insiders 33.1% Other 5%+ holders 4.5% Institutions (31 holders) 23.3% Public and other holders 39.1%
HolderTypeShares% of sharesAs of
Fairmount Funds Management LLC
Director, 10% owner
Insider 687,789 16.34% 2026-10-13
Robert W Postma
Director · +11,237 options
Insider 514,691 12.23% 2026-10-13
Price Adrian 5%+ holder (13D) 189,061 4.49% 2026-02-24
Jaime Vieser
Director · +6,650 options
Insider 85,914 2.04% 2026-10-06
Holger Weis
CEO · +154,580 options
Insider 49,047 1.17% 2026-10-06
Michael Allen Jerman
Director · +3,200 options
Insider 44,749 1.06% 2026-10-06
Ferdinand Groenewald
Vice President of Finance · +8,500 options
Insider 10,775 0.26% 2025-08-18

Share count 4,208,359 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TCRT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TCRT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.